Long-Term Effects of Risperidone in Children With Autism Spectrum Disorders: A Placebo Discontinuation Study

Troost, Pieter W.; Lahuis, Bertine; Steenhuis, Mark-Peter; Ketelaars, Cees; Buitelaar, Jan K.; Engeland, Hermán van; Scahill, Lawrence; Minderaa, Ruud B.; Hoekstra, Pieter J.

doi:10.1097/01.chi.0000177055.11229.76

Cited by 173 publications

(96 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two large, multisite, randomized, controlled trials have confirmed the short-term efficacy of risperidone for these severe disruptive behaviors in youth with ASDs, [162][163][164][165] and 2 open-label studies, each with a double-blind discontinuation component, have suggested long-term benefits and tolerance. 166,167 Potential adverse effects include but are not limited to excessive appetite and weight gain, insulin resistance, dyslipidemia, hyperprolactinemia, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, QTc prolongation, dry mouth, urinary retention, constipation, seizures, hematologic abnormalities, and sedation.…”

Section: Psychopharmacologymentioning

confidence: 99%

Management of Children With Autism Spectrum Disorders

Myers¹,

Johnson²

2007

Pediatrics

921

485

View full text Add to dashboard Cite

Pediatricians have an important role not only in early recognition and evaluation of autism spectrum disorders but also in chronic management of these disorders. The primary goals of treatment are to maximize the child's ultimate functional independence and quality of life by minimizing the core autism spectrum disorder features, facilitating development and learning, promoting socialization, reducing maladaptive behaviors, and educating and supporting families. To assist pediatricians in educating families and guiding them toward empirically supported interventions for their children, this report reviews the educational strategies and associated therapies that are the primary treatments for children with autism spectrum disorders. Optimization of health care is likely to have a positive effect on habilitative progress, functional outcome, and quality of life; therefore, important issues, such as management of associated medical problems, pharmacologic and nonpharmacologic intervention for challenging behaviors or coexisting mental health conditions, and use of complementary and alternative medical treatments, are also addressed.

show abstract

Section: Psychopharmacologymentioning

confidence: 99%

Management of Children With Autism Spectrum Disorders

Myers¹,

Johnson²

2007

Pediatrics

921

485

View full text Add to dashboard Cite

show abstract

“…Risperidone is an atypical antipsychotic drug is found to be effective in treating schizophrenia, bipolar disorder, and behavioral problems including hyperactivity, aggressiveness, and irritability associated with autism [6]. The commonly described adverse effects include insomnia, agitation, anxiety, fatigue, and extrapyramidal symptoms, such as the acute dystonia as seen in our patient [7].…”

Section: Discussionmentioning

confidence: 99%

Risperidone induced angioedema with concurrent EPS symptoms: a case report and review of literature

Samra

Kant

Chow

2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Angioedema has recently been reported as a side effect associated with the antipsychotic risperidone. We report a case of dystonia with concurrent angioedema due to risperidone. A 40-year-old male with a history of schizophrenia was started on 3 mg of risperidone BID and developed perioral and periorbital edema along with increased muscle rigidity and hand tremor within 24 h of initial administration. His symptoms abated after cessation of risperidone and intravenous administration of corticosteroids and antihistamine. This case study adds to the current literature, which has already established angioedema as a dose-dependent side effect of risperidone. Moreover, this case study aims to increase awareness about the potential for the simultaneous occurrence of angioedema and extrapyramidal symptoms, and promotes vigilance among prescribers so that the life-threatening consequences of such effects can be avoided.

show abstract

“…Studies have shown that risperidone is a well-tolerated drug that has positive effects on the behavioral disorders frequently associated with autistic spectrum disorder 20 . The short-term benefit of the use of risperidone for the control of severe symptoms, irritability and hyperactivity in pediatric autistic patients appears to have been well-established 21,22 . The continued use of risperidone beyond six months has also been shown to be effective, significant weight gain being considered the principal side effect, followed by anxiety, fatigue and somnolence 21 .…”

Section: Discussionmentioning

confidence: 99%

“…The short-term benefit of the use of risperidone for the control of severe symptoms, irritability and hyperactivity in pediatric autistic patients appears to have been well-established 21,22 . The continued use of risperidone beyond six months has also been shown to be effective, significant weight gain being considered the principal side effect, followed by anxiety, fatigue and somnolence 21 . discontinuation of the use of risperidone after six months has been associated with a rapid return of dysfunctional and aggressive behavior in the majority of patients, indicating that this drug may require long-term use 23 .…”

Section: Discussionmentioning

confidence: 99%

Control of psychomotor agitation and aggressive behavior in patients with autistic disorder: a retrospective chart review

Novaes¹,

Pondé²,

Freire

2008

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Objective:To evaluate the efficacy of pharmacotherapy on the symptoms of psychomotor agitation and aggressive behavior in a sample of patients with autistic spectrum disorder. Method: The charts of all patients with a diagnosis of autistic spectrum disorder, receiving care for psychomotor agitation and/or aggressive behavior in two psychiatric outpatient departments between 2001 and 2006, were reviewed. The Clinical Global Impression-Severity and -Improvement scales (CGI-S and CGI-I) were applied to the data retrieved from the charts. Results: The majority of the 26 patients included were treated with second-generation antipsychotics. A positive, statistically significant correlation was found between the implementation of pharmacotherapy and a reduction in CGI-S scores (p<0.05). Treatment response in patients with no mental retardation was better than in those mentally retarded (p<0.05). The majority of patients in whom clinical improvement was found following implementation of treatment had participated in at least one form of intervention therapy in addition to the principal treatment (p<0.05). Conclusion: Secondgeneration antipsychotics seem to reduce psychomotor agitation and aggressive behavior in patients with autistic spectrum disorder; however, further studies are required to evaluate the side effects of these drugs in relation to their beneficial effects.Key wordS: antipsychotics, pharmacological, retrospective, autistic disorder, treatment. Controle da agitação psicomotora e agressividade em pacientes com autismo: estudo retrospectivo de revisão de prontuárioResumo -Objetivo: Avaliar a eficácia do tratamento farmacológico dos sintomas de agitação psicomotora e agressividade em amostra de pacientes com transtorno do espectro autista. Método: Foram revisados os prontuários de pacientes com diagnóstico de transtorno do espectro autista que procuraram atendimento por apresentarem agitação psicomotora e/ou heteroagressividade, atendidos entre 2001 e 2006, em dois ambulatórios de psiquiatria. Para avaliação da evolução dos pacientes aplicou-se às informações do prontuário a escala de Impressão Clínica Global Sintomas (ICG-S) e a Impressão Clínica Global Melhora (ICG-M). Resultados: A maioria dos 26 pacientes estava em tratamento com antipsicóticos de segunda geração. Houve correlação positiva e estatisticamente significativa entre a introdução do tratamento farmacológico e a redução nos escores da ICG-S (p<0,05). A evolução do tratamento farmacológico foi melhor para os pacientes sem retardo mental do que para aqueles com retardo mental (p<0,05). A maioria dos pacientes que obteve melhora clínica com o tratamento participava de ao menos uma intervenção auxiliar ao tratamento principal (p<0,05). Conclusão: os antipsicóticos de segunda geração parecem reduzir a agitação psicomotora e agressividade em pacientes com transtorno do espectro autista no Brasil. É necessário que se avaliem os efeitos colaterais em relação aos efeitos benéficos dessas drogas.

show abstract

Long-Term Effects of Risperidone in Children With Autism Spectrum Disorders: A Placebo Discontinuation Study

Cited by 173 publications

References 24 publications

Management of Children With Autism Spectrum Disorders

Management of Children With Autism Spectrum Disorders

Risperidone induced angioedema with concurrent EPS symptoms: a case report and review of literature

Control of psychomotor agitation and aggressive behavior in patients with autistic disorder: a retrospective chart review

Contact Info

Product

Resources

About